AACR 2022: Accounting for genetic factors that cause normal variations in PSA levels may improve the accuracy of prostate cancer detection
The accuracy of prostate-specific antigen (PSA) screening for prostate cancer could be improved by accounting…
Browsing: AACR
AACR 2022: Leukaemia patients with certain gene regulation patterns may be less likely to respond to CAR T therapy
Acute lymphoblastic leukaemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR…
AACR 2022: Characterisation and functional analysis of microbiome in cancer
During the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 8-13, 2022, researchers…
AACR 2021: Neoadjuvant nivolumab plus chemotherapy increased pathological complete response rate in CheckMate-816 lung cancer trial
Adding nivolumab to chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer…
AACR 2021: Unselected autologous tumour infiltrating lymphocyte therapy shows early promise in patients with metastatic melanoma
Treatment with unselected autologous tumour infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with…
AACR 2021: Novel approach to PRMT5 inhibition that selectively targets the PRMT5/MTA complex in MTAP-deleted cancer models
Mirati Therapeutics, Inc. announced initial preclinical results evaluating its investigational synthetic lethal PRMT5 inhibitor in…
AACR 2021: FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers
Clinical trial results of RET kinase inhibitor selpercatinib show that the targeted therapy was effective…
AACR2021: Early-onset colorectal cancers – patients of different races
Racial differences in genetic mutations were observed among early-onset colorectal cancers (CRC), according to data…
AACR 2021: Level of chromosomal abnormality in lung cancer may predict immunotherapy response
Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy…
AACR 2021: Personalised cancer vaccine given after adjuvant therapy safe, shows early efficacy in multiple tumour types
Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and…